When the vitreous humour shrinks, the strong attachment results in a pulling force on the retina, which may lead to visual distortion, decreased visual acuity and central blindness. When the disease progresses the traction may eventually result in the formation of a hole in the macula (called a macular hole).
JETREA ® breaks down the protein fibers which cause the abnormal traction between vitreous and macula that causes VMT. By dissolving these proteins, JETREA ® releases the traction, and helps to complete the detachment of the vitreous from the macula.
JETREA ® can also be used when VMT has progressed and caused a small hole in the macula (central part of the light-sensitive layer at the back of the eye).
It is estimated that 250,000 to 300,000 patients in Europe alone suffer from this condition. [ 1 ]Prof. Albert Augustin, Ophthalmology Department Head at Klinikum Karlsruhe, said: " The introduction of JETREA ® into Germany represents a significant advancement in the way retina specialists can treat vitreomacular traction and certain stages of macular holes. These vision-threatening conditions, associated with many common retinal disorders, are more frequently identified due to the advancement of new ophthalmic diagnostics, optical coherence tomography, and had been previously addressed by the limited options of either physician observation or vitrectomy. JETREA ® now offers a new and effective treatment option, particularly for those patients whose conditions are not yet advanced enough to warrant surgery, to help physicians restore patients' vision and improve overall quality of life . " Currently the only available treatment in the EU is 'observation' or 'watchful waiting' until a patient becomes a surgical candidate, usually at a late stage of the disease. [ 2 ] , [ 3 ] A patient would then receive a surgical procedure and repair of the retina. However, for many patients this is not a suitable option, as irreversible damage to the retina may have already occurred. [ 4 ] , [ 5 ] ThromboGenics continues to work closely with Alcon to help develop the necessary infrastructure so that patients across Europe and beyond can access this innovative medicine and receive JETREA ® as soon as it becomes available in the respective countries. References